The weight loss line is one of the newest additions to a lot of med spa menus, and the easiest one to get in trouble with. Every other chapter in this guide has dealt with Google's rules. This one adds a second rulebook, because when a med spa advertises compounded semaglutide or tirzepatide, the FDA has started reading the ads too.
This chapter isn't legal advice, and your state may stack its own rules on top. But the federal picture is clear enough to write ads by, and most of what keeps a med spa safe with the FDA also keeps it safe with Google.
The FDA Told Compounders What They Can't Say. It Reaches Your Ads Too.
In February 2026, the FDA announced it would act against non-approved GLP-1 drugs and spelled out what their marketing can't claim. In promotional materials, companies "cannot claim that non-FDA-approved compounded products are generic versions or the same as drugs approved by FDA." The FDA added that they also can't say compounded drugs use the same active ingredient as the approved ones, or that compounded drugs are clinically proven to produce results for the patient.
Read that list against a typical med spa weight loss page. "Generic Ozempic." "Same medication as Wegovy, a fraction of the price." "Clinically proven weight loss." Every one of those phrases is on the FDA's list.
This isn't aimed only at telehealth companies. The FDA has already sent a warning letter to a med spa after reviewing its website. The page paired compounded products with brand names, lines like semaglutide followed by Wegovy in parentheses. The FDA's letter said those claims "imply that your products are the same as an FDA-approved product when they are not," and called the products misbranded as a result.
One more item from the FDA's March 2026 round of warning letters to telehealth sellers: the agency objected to firms branding compounded drugs with their own company name or trademark without explaining where the product comes from. A med spa that sells its weight loss shot under a catchy house name should make sure the page says plainly what's actually in the syringe and that it's compounded.
The Shortage Is Over, and So Is the Compounding Grace Period
For a while, compounded GLP-1s filled a real gap. Brand-name semaglutide and tirzepatide were on the FDA's shortage list, and the FDA allowed compounding pharmacies more room while supply caught up.
That period is over. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. The extra enforcement leeway for compounders ended during 2025. In April 2026, the FDA proposed keeping semaglutide, tirzepatide and liraglutide off the list of substances large outsourcing pharmacies can compound from, finding no clinical need for it.
Some med spas advertise semaglutide "with B12" as if the added vitamin makes it a different product. The FDA's compounding guidance addresses that directly: a product that combines semaglutide with another ingredient, such as vitamin B12, can still count as "essentially a copy" of the approved drug when it's given the same way and the strengths are close. Adding a vitamin doesn't turn a copy into something new, and it shouldn't become the headline either.
The FDA's own consumer page now says compounded drugs "should only be used in patients whose medical needs cannot be met by an FDA-approved drug." For advertising, the practical effect is simple. A compounded GLP-1 isn't a cheaper copy of a brand-name drug, and an ad can't treat it like one.
Google Still Won't Sell You the Drug Name as a Keyword
This part hasn't changed since Chapter 5. A drug name can sit in your ad copy and on your page, but buying it as a keyword takes a certification almost no in-person med spa qualifies for. So the weight loss line runs on searches like "medical weight loss near me," "weight loss injections" and "weight loss clinic," not on "semaglutide" or "tirzepatide."
That restriction turns out to point in the same direction as the FDA's. The med spas that do well here aren't selling a drug. They're selling a supervised program.
The Safest Weight Loss Page Sells the Program, Not the Drug
Two practices in our example market, Miami, show what that looks like.
CMA Miami's medical weight loss page describes the program first: lab work, a health history and physical, and a consultation with a licensed provider, with weekly body composition tracking and a dietitian. The drug names don't appear. Instead, the page says: "Ask About Medication Options at Consultation."
Blonde Girl Aesthetics takes the same route. Its medical weight loss page talks about ongoing guidance and regular check-ins with the practice's nurse practitioner. It doesn't name semaglutide or tirzepatide at all.
This approach solves two problems at once. The page makes no sameness claim for the FDA to object to. And it sells what the client actually needs to trust: a clinician who checks her labs, adjusts her dose and sees her every few weeks.
Your ads can follow the same pattern. Headlines about the program, the provider and the check-ins. The medication conversation happens at the consultation, where a clinician can have it properly.
Google Bans the Ten-Pounds-in-a-Month Promise Before the FDA Ever Sees It
Weight loss ads trip Google's own rules long before the FDA gets involved. Google's misrepresentation policy rules out "claims of unrealistic weight loss within a specific time frame or requiring little effort," and its example is an ad promising you can eat whatever you want and lose ten pounds in a month.
That catches a lot of what weight loss ads naturally want to say. "Drop two sizes by summer." "Lose 20 pounds in 8 weeks." "No diet, no gym." Even when some clients do get those results, Google treats an unusual outcome presented as the likely one as misleading.
The safer version describes the process honestly: supervised by a licensed provider, dosing adjusted over time, check-ins built in. The results belong in reviews and testimonials, labeled as individual experiences, as Chapter 8 covered.
A Price That Looks Too Good Is on the FDA's Red-Flag List
The FDA's consumer page lists warning signs for patients shopping for GLP-1 drugs. One of them is a seller that "offers medicine at deep discounts or prices that seem too good to be true."
The price landscape has moved, too. The makers now sell brand-name drugs direct to self-pay patients. Novo Nordisk lists Wegovy pens at $349 a month after an introductory rate, and Eli Lilly lists Zepbound from $299 to $699 a month depending on the dose. An ad shouting "Semaglutide $99 a Month" doesn't just look like a bargain anymore. It looks like exactly the kind of offer the FDA tells patients to question, and it invites the brand comparison the FDA has banned.
Google's dishonest pricing rules add a second requirement: the ad and page have to make the full cost clear. For a weight loss program, that means the drug, the visits, the labs and anything else the client will pay for. A low monthly number that leaves out the rest is the kind of hidden cost Google's policy targets.
If you publish a price, publish the whole program price and what it includes.
Before-and-After Photos Have to Come From Your Own Clients
Weight loss before-and-after photos are persuasive, which is why they get abused. In July 2025, the FTC acted against a telehealth weight loss company that, according to the complaint, used testimonials and before-and-after photos from people who weren't its clients and had never used GLP-1 drugs.
For a med spa, the rule is simple: every photo is a real client of yours, with written consent, and every testimonial reflects that client's real experience. Label results as individual, because they are.
Then apply Chapter 10's image rules. Body photos that show too much skin run into Google's nudity policy, and they're restricted on YouTube and the display network even when a photo is real and consented. Clothed progress photos, a client in the same outfit months apart, work almost everywhere.
A Clinician Reads Every Weight Loss Ad Before It Runs
Weight loss is the one line where the person who approves the ads should hold a medical license. Have your medical director or supervising clinician read every headline, description and landing page for the weight loss program before it goes live, and again whenever the offer changes.
Give them a short checklist:
- No "generic," "same as," "same active ingredient" or "clinically proven" language about a compounded drug.
- No specific pounds-in-a-time-frame promises.
- A price only if it's the full price, with what it includes.
- Every photo and testimonial from a real, consenting client.
- A clear statement, on the page, of what the medication is and that a clinician decides whether it's right for you.
- No "with B12" or house-brand framing that suggests the compounded product is a different, better drug.
State medical boards and state advertising rules can add requirements on top of these. Your clinician, and if needed a healthcare attorney in your state, are the right people to check those.
Next: Tell Clients Who Does the Injecting
The last chapter goes back to the question clients ask before almost any treatment: who's going to do this? Nurse, nurse practitioner, physician assistant, physician. What your ads can say about credentials, and how to answer that question before the client has to ask it, is in Chapter 15.
If you're joining the guide here, start at the Google Ads for Med Spas guide home; the weight loss line runs on the same foundation as everything else. Chapter 5 covers the drug-name keyword rules in full.
In the med spa accounts we manage through our Google Ads management, weight loss ads don't go live until the supervising clinician has signed off on every line.
